Omega Therapeutics — Company Overview, News & Financial Data
Omega Therapeutics develops DNA-targeting, mRNA-expressing therapies using its proprietary platform to revolutionize treatment across diseases.
About Omega Therapeutics
Omega Therapeutics (NASDAQ:OMGA) specializes in harnessing the power of genomic programming to develop a new class of DNA-sequence-targeting, mRNA-expressing therapies with the objective of revolutionizing the treatment across multiple disease areas. Their projects primarily focus on leveraging their proprietary Omega Epigenomic Programming™ platform to precisely tune gene expression, without altering the native DNA sequence, facilitating the development of therapies aimed at a broad range of diseases including oncology, regenerative medicine, and autoimmune diseases. Omega aims to pioneer a new era of genomic medicine, with the goal of unlocking the full potential of the human genome to conquer diseases at their genetic roots.
Snapshot
Operations
Products and/or services of Omega Therapeutics
- OTX-2002, a programmable epigenetic mRNA therapy targeting the MYC oncogene for hepatocellular carcinoma.
- OTX-2101, addressing solid tumors through epigenetic modulation.
- Development of a platform for modularly programming or reprogramming gene expression without altering the DNA sequence.
- Partnerships aimed at expanding the application of epigenetic therapy across various diseases.
Omega Therapeutics executive team
- Dr. Kaan Certel Ph.D.President, CEO & Director
- Dr. David A. Berry M.D., Ph.D.Founder
- Ms. Barbara Y. Chan CPAPrincipal Financial Office, Principal Accounting Officer & Chief Accounting Officer
- Dr. Jennifer Nelson Ph.D.Chief Scientific Officer
- Ms. Eva StroynowskiSenior Vice President of Investor Relations & Corporate Affairs
- Mr. Anthony MullinChief People Officer
- Mr. Charles O'Donnell Ph.D.VP and Head of Computational Genomics & Data Sciences
- Dr. Joe Newman Ph.D.Senior Vice President of Early Discovery